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Helicobacter pylori is a common and persistent human pathogen of the gastric mucosa. Surfactant protein D
(SP-D), a component of innate immunity, is expressed in the human gastric mucosa and is capable of
aggregating H. pylori. Wide variation in the SP-D binding affinity to H. pylori has been observed in clinical
isolates and laboratory-adapted strains. The aim of this study was to reveal potential mechanisms responsible
for evading SP-D binding and establishing persistent infection. An escape variant, J178V, was generated in
vitro, and the lipopolysaccharide (LPS) structure of the variant was compared to that of the parental strain,
J178. The genetic basis for structural variation was explored by sequencing LPS biosynthesis genes. SP-D
binding to clinical isolates was demonstrated by fluorescence-activated cell sorter analyses. Here, we show that
H. pylori evades SP-D binding through phase variation in lipopolysaccharide. This phenomenon is linked to
changes in the fucosylation of the O chain, which was concomitant with slipped-strand mispairing in a poly(C)
tract of the fucosyltransferase A (fucT1) gene. SP-D binding organisms are predominant in mucus in vivo
(P  0.02), suggesting that SP-D facilitates physical elimination. Phase variation to evade SP-D contributes to
the persistence of this common gastric pathogen.
The gram-negative motile bacterium Helicobacter pylori is a
gastroduodenal pathogen that is a causative agent of chronic
gastritis, associated with peptic ulcer development, and a co-
factor in the development of adenocarcinoma and mucosa-
associated lymphoma (13, 14, 29, 40). H. pylori colonizes more
than one-half of the world’s population. However, only 15% of
infected individuals are clinically symptomatic (38). While it is
clear that the organism induces a strong innate and adaptive
immune response leading to active inflammation in the gastric
mucosa, the ability of H. pylori to establish persistent infection
so efficiently has not been adequately explained. H. pylori pos-
sesses a number of virulence factors, and some, such as urease
and flagella, contribute to its persistence (12, 31), whereas
others, such as the product of the cytotoxin-associated gene A
(CagA, encoded in the cag pathogenicity island) and vacuolat-
ing cytotoxin (VacA), appear to confer increased virulence (7,
21). Nevertheless, the interplay between H. pylori and host
defense mechanisms requires further dissection to establish
the mechanisms of persistence.
H. pylori occupies a unique ecological niche in the gastric
mucus and on the surfaces of epithelial cells. Within this en-
vironment, the organism minimizes recognition by the innate
immune system and evades phagocytosis because neutrophils
and macrophages do not appear to traverse the gastric epithe-
lium. However, within the mucus layer, there is a further com-
ponent of the innate immune system, surfactant protein D
(SP-D) (37). SP-D, a member of the collectin family, is a
multimeric protein with 12 carbohydrate recognition domains
that displays an affinity preference for maltose, mannose, and
glucose (9, 42). SP-D was originally identified as a component
of surfactant in the lung, where it is mainly expressed in alve-
olar type II and Clara cells (8, 53). However, a growing body of
evidence confirming the presence of SP-D at other mucosal
sites in close contact with numerous pathogens suggests that
SP-D plays a role in innate immunity at mucosal surfaces as a
pathogen-associated molecular pattern (PAMP) recognition
receptor (24). Specifically, SP-D has been shown to be involved
in antibody-independent pathogen recognition and clearance
(16, 28). Moreover, there is evidence for the interaction of
SP-D with a wide range of microorganisms, including viruses
(such as influenza A virus), fungi (such as Aspergillus fumigatus
and Saccharomyces cerevisiae), and gram-negative bacteria
(such as Escherichia coli and Klebsiella pneumoniae), inducing
their aggregation in a calcium-dependent and lectin-specific
manner (1, 15, 18, 19). Furthermore, SP-D aggregation of
microorganisms can enhance phagocytosis by neutrophils and
macrophages (10, 22, 39), and SP-D binding has been impli-
cated in bactericidal activity (55).
Whereas most studies have focused on the interaction of
SP-D with lung pathogens (30), we have recently demonstrated
the expression of SP-D in gastric mucosa and the interaction
between SP-D and H. pylori (37). In addition, experiments in
SP-D-deficient (SP-D/) mice have revealed that coloniza-
tion with Helicobacter was more common in the absence of
SP-D (W. Khamri, M. L. Worku, A. E. Anderson, M. M.
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Walker, S. Hawgood, K. B. M. Reid, H. W. Clark, and M. R.
Thursz, submitted for publication). These data suggest that this
component of innate immunity is likely involved in the immune
response to H. pylori in the stomach. Although certain redun-
dancy of innate immune mechanisms may occur, for successful
persistent infection by H. pylori to occur implies that either
SP-D-mediated immunity is ineffective or that the bacterium
can evade SP-D binding, or both.
Lipopolysaccharide (LPS), the main component of gram-neg-
ative bacterial cell walls, is the putative target of SP-D binding
(19), including that of H. pylori (37). The LPS of H. pylori strains
expresses fucosylated oligosaccharides known as Lewis (Le) an-
tigens that are structurally related to human blood group anti-
gens. It has been shown that 80% of strains express the type 2
glycoforms Lex and/or Ley, whereas less than 5% contain the type
1 glycoforms Lea and Leb (34, 54). H. pylori LPSs display marked
antigenic variation and may be used as the basis for differentiation
between the strains (34). Phase variation is the reversible switch-
ing of surface epitopes, including those of LPS (36), and is genet-
ically controlled by on-and-off switching of specific genes involved
in LPS biosynthesis, particularly Lewis antigen mimicry (4, 5, 47).
It has been suggested that phase variation contributes to the
heterogeneity of H. pylori and might contribute to a better adap-
tation to the host (3, 36).
This study investigated the relationship between SP-D bind-
ing and LPS phase variation in vitro and in vivo, with the
specific aim of revealing potential mechanisms of bacterial
persistence due to avoidance of recognition by SP-D, a mem-
ber of the collectin family of innate immunity molecules.
MATERIALS AND METHODS
Bacterial strains and growth conditions. H. pylori reference strains ATCC
26695 and J178 were kindly donated by M. Anyim (London School of Hygiene
and Tropical Medicine, London, United Kingdom) and J. C. Atherton (Division
of Gastroenterology, University Hospital, Nottingham, United Kingdom), re-
spectively. H. pylori J178 was originally isolated and typed at the Vanderbilt
University School of Medicine (Nashville, TN) from a patient with nonulcer
dyspepsia. This strain is motile and characterized by the expression of the viru-
lence factors CagA and VacA. These H. pylori strains were grown on blood agar
medium composed of Columbia agar base (Oxoid, Basingstoke, United King-
dom) supplemented with 10% (vol/vol) laked horse blood (Oxoid). The bacterial
cells were then incubated at 37°C in a microaerobic atmosphere generated by
Anaerocult C gas-generated envelopes (Oxoid) for 48 h.
Isolation of clinical isolates from mucus versus tissue of biopsy samples.
Antral biopsy specimens were collected from patients undergoing upper gastro-
intestinal endoscopy for dyspepsia after Ethical Committee approval and written
consent. Patients were selected if they were over the age of 18 and were suffering
with dyspepsia. Patients who had been on proton pump inhibitors or antibiotics
within the previous 3 months were excluded. All patients had chronic active
gastritis that was demonstrated histologically. The whole biopsy sample was
transferred aseptically onto the surface of a selective agar plate consisting of
blood agar supplemented with H. pylori selective supplement (DENT; Oxoid).
The mucus layer was carefully scrubbed off the surface of the biopsy specimen
using a 1-l loop and streaked onto the plate. Subsequently, the intact tissue
portion was lifted and transferred to a new selective agar plate and rubbed over
the surface. After inoculation, the plates were incubated microaerobically for up
to 5 days at 37°C. The relative proportion of isolated bacteria in mucus to tissue
was 90:10. A sufficient number of colonies was tested to ensure they were
representative of the overall bacterial population.
Bacterial standard curves. Bacterial strains were resuspended in Tris-buffered
saline, pH 7.4 (TBS), and the optical density at 550 nm (OD550) was determined
using a Smart Spec 3000 spectrophotometer (Bio-Rad, Hemel Hempstead,
United Kingdom). Subsequently, 10-fold serial dilutions (up to a 106 dilution)
were made, the OD values were determined for each dilution, and then aliquots
(10 l) of each dilution were plated onto blood agar. After incubation, colonies
were counted and a standard curve was produced that correlated OD with CFU.
H. pylori agglutination assay. Native human SP-D (nhSP-D) was purified from
the lung lavage fluid of patients with alveolar proteinosis according to the
method of Strong et al. (48). The purity of SP-D preparations was greater than
95% as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(48). SP-D binding to H. pylori strains was assessed using an agglutination assay
as previously described (37). The bacterial cells were incubated with 2.5 g/ml
nhSP-D in the presence of 10 mmol/liter CaCl2 for 1 h at 37°C, and agglutination
was assessed as the difference in the OD770 of suspensions of bacterial cells after
incubation for 45 min in the presence and the absence of nhSP-D.
Generation of SP-D escape variant. The escape variant of J178 (J178V) was
generated following the agglutination of bacterial cultures derived from a single
colony of the H. pylori parental strain, J178, in the presence of 2.5 g/ml nhSP-D
and 10 mmol/liter CaCl2. The agglutinate was filtered through a 2-m filter, and
the free bacteria were collected and cultured on blood agar. This process was
repeated for four cycles to generate J178V.
Restriction fragment length polymorphism (RFLP) analysis. Genomic DNA
was extracted from H. pylori J178 and J178V using a standard technique involving
proteinase K digestion and ethanol precipitation. Sequence data for the urease
gene cluster (ureA, ureB, ureC, and ureD) (20) were used to design primers to
amplify a portion of the ureC gene as described previously (32). The forward
primer was 5-TTTGGGACTGATGGCGTGAGGGGTAA-3, the reverse
primer was 5-GGACATTCAAATTCACCAGGTTTTGAGG-3, and the pre-
dicted amplification product was 1,132 nucleotide pairs in length. PCR ampli-
fication was performed in a 50-l reaction volume with 1 PCR buffer;
0.125 mmol/liter MgCl2, 200 mol/liter (each) dATP, dCTP, dGTP, and dTTP
(Roche Diagnostics, East Sussex, United Kingdom); 100 ng of each of the
forward and reverse primers (Genosys, Haverhill, United Kingdom); 2.5 U of
Taq polymerase (Gibco BRL, Paisley, United Kingdom); and 10 l of template
DNA sample (containing between 10 and 100 ng of DNA). Reactions were
performed with a cycling program of 25 cycles of 94°C for 1.5 min, 48°C for 1 min,
and 72°C for 2 min. The ureC amplicon was examined for homogeneity and yield
by separation on a 0.8% agarose gel. A volume of 10 l of the PCR product was
digested using the appropriate restriction enzymes (NdeII and CfoI) (Roche
Diagnostics), which were chosen because of their increased discriminatory ability
in comparison to HindIII (data not shown). Digestion products were electro-
phoresed on a 2% agarose gel.
Competitive inhibitory SP-D enzyme-linked immunosorbent assay (ELISA)
for determination of SP-D binding to LPS. LPS preparations were extracted
from biomass of H. pylori J178 and J178V that had been grown on solid medium,
using hot-phenol water treatment as described previously (35). SP-D binding to
LPSs extracted from J178 and J178V was tested using the competitive inhibitory
ELISA described elsewhere (37). Briefly, LPSs were preincubated with SP-D
before addition to mannan-coated Maxisorb Immunoplates (Life Technologies,
Paisley, United Kingdom). The plates were washed and sequentially incubated
with biotin-labeled rabbit anti-SP-D polyclonal antibody (23), with ExtrAvidin-
peroxidase conjugate (Sigma-Aldrich, Haverhill, United Kingdom), and with
tetramethylbenzidine substrate (Bio-Rad, Hemel Hempstead, United Kingdom).
Readings were carried out at 450 nm (Titertek Multiscan PLUS MKII) (37). The
50% inhibitory concentrations (IC50) were calculated using GraphPad Prism
software.
FACS analyses of SP-D binding to whole bacteria. Bacterial cell suspensions
were adjusted to an OD550 of 0.24 (106 bacteria/ml) and washed three times in
TBS by centrifugation at 1,700  g for 8 min. The cells were then resuspended
in TBS, and 100-l aliquots were added to fluorescence-activated cell sorter
(FACS) tubes and incubated in the presence of 2.5 g/ml human recombinant
SP-D, which consists of three carbohydrate recognition domains and the -he-
lical neck region (6), with 10 mmol/liter CaCl2 for 1 h at 37°C. The cells were
then washed twice in TBS and incubated in the presence of 1/10,000 biotin-
labeled rabbit anti-recombinant SP-D antibody (23) for 1 h at 37°C. Subse-
quently, the cells were washed and finally incubated in the presence of fluores-
cein isothiocyanate-streptavidin (Serotec, Oxford, United Kingdom) at a 1/1,000
dilution for 30 min in the dark at room temperature. The cells were then washed
three times and resuspended in 1% paraformaldehyde in phosphate-buffered
saline (10 mmol/liter phosphate buffer, 2.7 mmol/liter KCl, and 137 mmol/liter
NaCl, pH 7.4) solution. Incubation of the bacterial cells in the presence of
100 mmol/liter maltose and a goat immunoglobulin G (IgG) isotype control
(R&D Systems, Oxon, United Kingdom) at 1/1,000 dilution were used as nega-
tive controls. The analysis was performed using a FACSCalibur flow cytometer,
and data were analyzed using CELLQuest software (Becton Dickinson,
Palo Alto, CA). The flow cytometer detectors were set as follows: forward
scatter  E-01, side scatter  413, and fluorescent channel 1  551. A total of
10,000 gated events were analyzed for each cell population. All experiments were
done in duplicate. The estimation of positively labeled cells was determined by
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setting an arbitrary cutoff gate at which discrimination between unstained (iso-
type control) and stained cell populations was detected. All experiments were
compared using the same cutoff gate. The estimated proportions of SP-D binding
cells were statistically compared between mucus and tissue isolates using Stu-
dent’s t test. Statistical significance was defined as a P value of 0.05.
LPS analysis with monoclonal antibodies. The expression of LPS epitopes,
particularly Le antigen related, by J178 and J178V whole bacteria was measured
in ELISA using specific monoclonal antibodies (MAbs) as described previously
(3–5, 11). Polystyrene 96-well microtiter plates were coated at 7.5  106 CFU/ml
with bacteria washed in 0.1 mol/liter phosphate-buffered saline, and the bacteria
were tested for reactivity with MAbs (1 g/ml). In addition, reactivity of anti-
bodies with purified LPSs of H. pylori J178 and J178V with which microtiter
plates were coated (50) was determined in ELISA as described previously (36)
and by Western blotting after electroblotting of LPSs from sodium dodecyl
sulfate-polyacrylamide gel electrophoresis gels (36). As outlined previously (27),
the specificities of the antibodies in the assays were validated by their ability to
bind the respective antigen from a panel of synthetic Le and blood group
antigens (Isosep AB, Tullinge, Sweden, and Dextra Laboratories, Reading,
United Kingdom).
LPS structural studies. Compositional analysis of H. pylori LPSs was per-
formed using gas-liquid chromatography and gas-liquid chromatography–mass
spectrometry as described elsewhere (20). Furthermore, detailed structural anal-
ysis was performed after the LPSs were subjected to standard mild acid hydro-
lysis, and the liberated saccharides were isolated using gel permeation chroma-
tography (36). The isolated saccharides were subjected to physical analysis using
nuclear magnetic resonance (NMR) spectroscopy (1H-, 13C-, and 31P-NMR) and
electrospray ionization mass spectrometry, as well as classical sugar and meth-
ylation analyses (36), and the structures of the core oligosaccharides and O
chains of the respective LPSs were established. Details of the structural analysis
will be reported in a separate paper (A. P. Moran, unpublished data).
DNA sequencing of LPS genes. Bacterial DNA was extracted using a standard
technique involving proteinase K digestion and ethanol precipitation. PCRs were
carried out in a 50-l volume at the specific annealing temperatures listed in
Table 1. The PCR products were immediately purified using a MinElute Extrac-
tion kit (QIAGEN, West Sussex, United Kingdom), and the products were
subjected to cloning into a pGEM-T Easy vector system (Promega, Southhamp-
ton, United Kingdom) according to the manufacturer’s instructions. The PCRs
were repeated twice, and at least five clones from each PCR of each gene and
each strain (J178, J178V, and J178V round 4) were sequenced. Of the cloned
products, 1 l was subjected to restriction digestion using EcoRI (New England
Biolabs, Herts, United Kingdom) for 2 h at 37°C to verify the presence of the
correct insert in each sample. The cloned products were sequenced using
3.2 pmol/liter of T7 and pUC/M13-Rev primers (5-TAATACGACTCACTA
TAG-3 and 5-CAGGAAACAGCTATGAC-3, respectively). Sequencing
was performed at the Sequencing Facility of the MRC-CSC Genetics
Core Facility (Imperial College, Hammersmith Campus, London, United
Kingdom).
Statistical analyses. Results were compared using the Student t test when
normally distributed or using the Mann-Whitney U test for nonparametric data.
Statistical significance was assumed for P values less than 0.05. All analyses were
performed using Graph Pad Prism 3.0.
RESULTS
Generation of the J178 escape variant (J178V). Observa-
tions in our previous study characterizing SP-D binding
and agglutination of H. pylori (37) revealed the presence of
H. pylori cells that are not susceptible to binding by SP-D. This
suggested that some bacterial cells lack a ligand for SP-D and
are therefore capable of evading SP-D binding. We isolated an
SP-D binding escape variant (J178V) in vitro after four cycles
of agglutination and filtration of the parental strain J178 (a
CagA-positive, VacA-positive laboratory-adapted strain) in
the presence of 2.5 g/ml nhSP-D and 10 mmol/liter CaCl2
(Fig. 1A). J178V was resistant to binding and agglutination,
even in the presence of excess concentrations (range, 2.5 to 12
g/ml) of SP-D (Fig. 1B).
Agglutination of H. pylori in vitro was used as a measure of
the relative binding of SP-D to J178 and J178V and to a
well-characterized reference strain, ATCC 26695. Agglutina-
tion was inhibited in the presence of maltose and EDTA,
demonstrating lectin-specific binding (Fig. 2A). In macroscopic
observations and in agglutination assays, the reference strain
ATCC 26695 had the highest binding to nhSP-D (	OD700 
0.189), whereas J178V showed the lowest binding (	OD700 
0.02). SP-D binding to J178 was fivefold higher than to J178V
(P  0.001) (Fig. 2A).
RFLP analysis of H. pylori J178 and J178V. In order to
demonstrate that H. pylori J178V is derived from H. pylori J178
rather than arising through a nonclonal isolate, RFLP analyses
were performed on DNAs extracted from both J178 and J178V
using ureC primers for amplification. The PCR protocol suc-
cessfully amplified a 1.1-kbp product which, when subjected to
restriction analysis using NdeII and CfoI restriction endo-
nucleases, yielded identical RFLP patterns for both strains
(data not shown), thereby indicating a high degree of genetic
relatedness.
Correlation between SP-D binding affinity of LPS and the
corresponding live bacteria. We sought to determine whether
disparity in affinities between different strains is related to com-
ponents of the bacterial cell surface. A competitive inhibitory
ELISA was therefore used to compare SP-D affinity to LPS mole-
cules extracted from H. pylori J178 and J178V by measuring IC50
values in the competitive inhibition assay. SP-D had the highest
affinity for J178 LPS (IC50  50.72 g/ml), whereas affinity for
J178V LPS was low (IC50  83.21 g/ml) (Fig. 2B). These results
TABLE 1. Primer sequences used in this study to amplify H. pylori candidate genes by PCR
Gene Primer sequence (5-3) PCR annealingtemp (°C)
Product
size (bp)
fuc T 2 Fuc1,2/F, ATGTTCCAACCCCTATTAGACGCC 52.9 1,428
Fuc 2/R, CTTTTTAACCCATCTCCTTAT
lpxA lpxA/F1, ATGAGTAAGATTGCAAAAACAG 52.9 813
lpxA/R2, TTATTCCTCTTGTTTTTCTTCG
rfaF rfaF/F1, ATGAGCGTAA ATGCACCCA 59 1,050
rfaF/R1, TGGCCATCTTTTAGCACTCC
fucT 1 Fuc1,2/F, ATGTTCCAACCCCTATTAGACGCC 55.5 1,278
Fuc1/RJ99, CAAACCCAATTTTTTAACCCATCT
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were consistent with those obtained with the corresponding live
bacterial strains (Fig. 2A). Binding was inhibited in the presence
of maltose and EDTA (data not shown).
Variation in Le expression in LPS. Antigenic variations in
the LPS structures of H. pylori J178 and J178V were explored
using a panel of MAbs directed at specific Le antigens (termi-
nal Lex, polymeric Lex, and terminal Ley) (3–5, 11). The reac-
tivities of these antibodies with whole bacterial cells of J178
and J178V in the ELISA revealed different reaction profiles.
The MAb specific for polymeric Lex bound strongly to both
strains, whereas that specific for terminal (monomeric) Lex
bound to J178V, but to a much lesser extent than to J178. In
FIG. 1. Representation of the generation of the escape variant, H. pylori J178V. (A) Phase-contrast microscopy shows J178 after agglutination
in the presence of 2.5 g/ml nhSP-D and 10 mmol/liter CaCl2. The agglutinated strain was filtered through 2-m filters, and the collected filtrate
was agglutinated and then filtered. The process was repeated for three additional cycles (4) to yield the escape variant. (B) Phase-contrast
microscopy of J178V showing no agglutination even in the presence of excess SP-D concentrations (range, 2.5 to 12 g/ml).
FIG. 2. Measurements of SP-D-mediated agglutination and SP-D binding of different H. pylori strains. (A) Agglutination was determined as
the difference in OD700 between suspensions of bacterial cells after incubation for 45 min in the presence and the absence of SP-D. The error bars
indicate standard deviations. (B) Inhibition of SP-D binding to mannan by H. pylori LPSs was demonstrated in dose-dependent competitive
inhibition of SP-D-mannan binding by LPSs extracted from H. pylori J178 and J178V. Curve fitting was performed using GraphPad prism software
(Prism 3.0).
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contrast, J178V expressed a terminal Ley epitope that was
present to a lesser extent on J178 (Table 2). Nevertheless, a
MAb against a conserved epitope in the LPS core, which was
used as a control, gave identical reactions with J178 and J178V
whole cells (Table 2). Likewise, analysis of purified LPSs of
J178 and J178V in immunoblotting and ELISA revealed the
same spectrum of reactivities as those observed with the whole
bacterial cells. In addition, however, these analyses showed
that J178 LPS expressed predominantly an H-1 epitope termi-
nally, but also to a lesser extent Lex and Ley units terminally, in
contrast to J178V LPS, which expressed a terminal Ley epitope
alone (data not shown).
A detailed structural investigation of LPS from H. pylori
J178 and J178V was undertaken using nuclear magnetic reso-
nance spectroscopy (Moran, unpublished). Both strains were
shown to contain an O-polysaccharide chain (smooth-form
LPS) with polymeric Lex. As shown in Fig. 3A and B, J178 LPS
expressed terminal H-1 antigen, with lower expression of ter-
minal Lex and Ley, consistent with the results of the antibody
probing studies described above. In contrast, J178V was found
to express terminal Ley alone, but with less modification of the
O chain by glucose and galactose and greater fucosylation than
in J178 LPS. Specifically, analyses revealed a lower degree of
fucosylation in J178 LPS than in the J178V LPS (10% versus
43%) and a higher degree of decoration with glucose (but also
with galactose) in J178 LPS than in J178V LPS (60% versus
20%). Furthermore, structural studies revealed the occurrence
of different core oligosaccharides in J178 and J178V LPSs (Fig.
3C and D). Compared with J178V LPS, a fourth heptose res-
idue is absent from the core of J178, and the first residue of the
O chain, N-acetylglucosamine, is in a 
(1, 2) rather than 
(1, 7)
linkage to the terminal heptose of the core oligosaccharide.
J178V SP-D escape variation is an example of phase varia-
tion. Although RFLP confirmed that H. pylori J178 and J178V
are derived from the same strain, there are clearly changes in
their LPS structures, which allows J178V to evade binding by
SP-D. SP-D binding to bacterial cells was demonstrated after
labeling with fluorescein isothiocyanate-conjugated antibody
using FACS analysis. This technique demonstrated that the
proportion of the H. pylori ATCC 26695 cell population bound
by SP-D was as high as 48% compared to 5.8% in the J178V
population (Fig. 4). Moreover, a higher proportion of cells of
the J178 population (44.9%) were capable of binding SP-D
than in the J178V population. As shown in Fig. 4, serial rounds
of culture (assigned rounds 1 to 4) of J178V in the absence of
SP-D selection pressure revealed that this switch was revers-
ible. A constant increase in the percentage of SP-D-bound cells
was seen as the cycle numbers increased. The binding of the
J178V cell population increased from 5.8% at round 1 to
24.5% at round 4, indicating reversion of a proportion of cells
in the population to the J178 SP-D binding phenotype of the
parental strain J178 population. Moreover, antibody probing
and structural analyses of LPS from the J178V round 4 popu-
lation showed reversion to the J178 phenotype (data not
shown). Furthermore, comparison of the maximal growth rate
of H. pylori J178 (8.58  104 CFU/hour) with that of J178V
(7.6  104 CFU/hour) showed that the former had a growth
rate advantage over the latter. Thus, in the absence of SP-D
selective pressure, there was a spontaneous switchback from
the J178V to the parental J178 phenotype, producing a repli-
cative advantage but also loss of the escape variation.
SP-D escape variation in vivo. The proportion of SP-D bind-
ing cells in ex vivo clinical isolates from mucus and tissue was
up to threefold lower than that with H. pylori ATCC 26695
(Fig. 4 and 5A), suggesting that SP-D exerts a significant se-
lection pressure in vivo. The mean value (standard deviation)
for isolates from tissue samples was 16.30%  0.95%, whereas
the mean value for isolates from mucus samples was 26.26% 
2.71% (Fig. 5B). In all patients, the proportion of SP-D bind-
ing cells was lower than that seen with the reference strain in
this study and with other collection strains (37). Nevertheless,
H. pylori SP-D binding cells are more frequent in mucus iso-
lates than in tissue isolates (P  0.02), indicating that SP-D
binding cells are concentrated in the mucus layer (Fig. 5B).
Genetic basis of escape variation. The genetic changes un-
derlying phase variation between H. pylori J178 and J178V
were sought by sequence analysis of genes involved in LPS
biosynthesis. The LPS structural variation described above,
particularly in the O chain, was used as a guide in selecting
H. pylori genes. Three candidate genes were sequenced, which
encode an -1, 3-fucosyltransferase A (fucT1) and an -1,
3-fucosyltransferase B (fucT2) and are involved in the synthesis
of Lex, Ley, and Lea, and an ADP-heptose-LPS heptosyltrans-
ferase II (rfaF) involved in synthesis of the LPS inner core
(2, 33, 34, 49). A UDP–N-acetylglucosamine acyltransferase
(lpxA) gene involved in lipid A synthesis (2, 33, 49) was used as
a control gene and showed no amino acid changes (Table 3).
Comparison of gene sequences between H. pylori J178 and
J178V showed no changes in the fucT2 gene. However, com-
parison of the full sequence of the cloned rfaF gene between
J178 and J178V showed a transition from T to C at codon 120
in J178V, leading to an amino acid substitution: a phenylala-
nine-to-leucine change (Table 3). In addition, we identified a
nucleotide deletion in the fucT1 gene at position 13 in J178,
leading to a frameshift and the induction of a termination
codon (TAG) at codon 6 in J178 (Table 3). Hence, the pre-
dicted protein sequence for J178 from this nucleotide sequence
is Met-Phe-Gln-Pro-Tyr-Stop, thereby prematurely terminat-
ing the translation process and, ultimately, resulting in the
production of a truncated protein. This is likely to explain the
lower degree of fucosylation in J178 than in J178V LPS re-
vealed by the NMR structural analyses (Fig. 3A and B). Se-
quencing of J178V, which spontaneously switched back to the
parental J178 phenotype in the absence of SP-D pressure
(Fig. 4), showed that this variant has reverted to the J178
parental genotype (Table 3).
TABLE 2. Investigation of Le antigen expression by H. pylori J178
and J178V on whole bacterial cells
Strain
MAb specificity a
Monomeric
LeX (6H3)
Polymeric
LeX (54.1F6A)
LeY
(Hp 151)
Core
(6C11)
J178    
J178V    
a Lewis antigen expression on whole bacterial cells as detected in ELISA.
Murine MAbs were 6H3 (IgM), 54.1F6A (IgM), Hp151 (IgG), and 6C11 for the
detection of monomeric (or terminal) Lex, polymeric Lex, Ley, and the core
oligosaccharide region, respectively (3, 4, 11). , OD492 0.5; , OD492 2.
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DISCUSSION
SP-D is a PAMP recognition receptor providing immediate
defense against microbial invasion as part of the innate im-
mune system at mucosal surfaces (10). Moreover, the impor-
tance of SP-D in the immune response against Helicobacter
infection has been revealed in experiments in the SP-D-defi-
cient (SP-D/) mouse, where colonization with Helicobacter
was more common in the absence of SP-D (Khamri et al.,
submitted). Although a certain redundancy of innate immune
FIG. 3. Structural differences between LPSs from H. pylori J178 and J178V. (A and B) Proposed structures of the O chains of J178 and J178V
LPSs, respectively. The O chain of H. pylori J178V had a higher degree of fucosylation (green) and a lower degree of glucose/galactose decoration
(dark blue) than that of J178. In addition to the terminal H-1 units (dark brown) shown in J178, alternate terminal units of Lex and Ley also
occurred to a lesser extent. (C and D) Proposed structures of the core oligosaccharides of J178 and J178V LPSs, respectively. Comparison of the
cores shows that a fourth heptose residue is absent and that N-acetylglucosamine of the O chain occurs in 
(1, 2) linkage to the terminal heptose
of the core in J178 (C) rather than in 
(1, 7) linkage, as in J178V (D). Fuc, L-fucose; Gal, D-galactose; Glc, D-glucose; GlcNAc, N-acetyl-D-
glucosamine; Hex, hexose; DD-Hep, D-glycero-D-manno-heptose; LD-Hep, L-glycero-D-manno-heptose; Kdo, 3-deoxy-D-manno-2-octulosonic acid;
PEtn, phosphorylethanolamine. The bracket around Fuc and Hex refers to an individual unit of the chain, and the numbers indicate how many
of this unit are in the chain. The arrows indicate the linkage.
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mechanisms may occur, to establish persistent infection, H.
pylori may develop mechanisms to evade SP-D binding and
hence avoid this important innate immune response. This
study identified and characterized the mechanism used by
H. pylori to avoid SP-D binding.
The outer leaflet of the cell wall of H. pylori, like those of
other gram-negative bacteria, is predominately composed of
LPS consisting of the hydrophilic O chain, the core oligosac-
charide region, and the hydrophobic lipid A moiety (34); the O
chain may express Lewis antigens (33). Serological probing of
whole bacterial cells in ELISA indicated that both the J178 and
J178V strains had high expression of polymeric Lex. However,
compared to H. pylori J178, which expressed a terminal (mo-
nomeric) Lex epitope, the variant strain J178V displayed a
higher expression of terminal Ley epitope. Likewise, analysis of
purified LPSs of J178 and J178V in immunoblotting and
ELISA revealed the same spectrum of reactivities as observed
with the whole bacterial cells but also showed that J178 LPS
expressed predominantly an H-1 epitope terminally and also to
a lesser extent Lex and Ley units terminally, in contrast to
J178V LPS, which expressed a terminal Ley epitope alone. As
well as confirming these results, structural studies found that
the O chain from J178V possessed a higher degree of fucosy-
lation and a lower degree of decoration with glucose (but also
with galactose) than J178. These results are consistent with
reports on the selectivity of SP-D binding to different monosac-
charides in vitro. Inhibition of SP-D binding to solid-phase
mannan by specific saccharides has demonstrated that SP-D
has a low affinity for fucose relative to its high affinity for
glucose or galactose (42). Hence, the changes in LPS structure
replacing glucose and galactose with fucose residues on the O
chain likely explain the changes in SP-D affinity for H. pylori
J178 and J178V.
Although serological probing indicated the occurrence of
some conservation of the inner core in LPSs of J178 and
J178V, structural analyses revealed a new type of core oligo-
saccharide in J178 LPS, where an N-acetylglucosamine is 
(1,
2) rather than 
(1, 7) linked in the J178 LPS. It is therefore
conceivable that changes in the core oligosaccharide region
also influence the binding of SP-D by H. pylori. From the
structural investigations, it would appear that changes in the
core oligosaccharide induce complementary changes in the O
chain, or vice versa. Therefore, at present, it is difficult to
determine whether the differences seen in the genes responsi-
ble for the synthesis of the O chain are primary or compensa-
tory, following the change in the core oligosaccharide region.
The availability of the complete genome sequences of two
FIG. 4. Switchback from H. pylori J178V to the phenotype of J178
as demonstrated by FACS analyses during serial rounds of culture
(assigned rounds 1 to 4) in the absence of SP-D. The proportions of
SP-D binding cells in the J178V cell population at different subculture
rounds were estimated starting from the original J178V population to
the fourth subculture round, compared to H. pylori J178 and ATCC
26695 populations. A treatment with 100 mmol/liter maltose was in-
cluded as a negative control in order to confirm the lectin-binding
specificity of SP-D.
FIG. 5. Determination of the presence of low and high SP-D bind-
ing affinity H. pylori clinical isolates and the presence of escape variants
in vivo. (A) Estimation of the proportions of binding cells in the
individual H. pylori cell populations of clinical isolates 1, 2, 3, and 4
from mucus (M1, M2, M3, and M4) and tissue (T1, T2, T3, and T4).
The bacterial populations from mucus samples displayed a higher
fluorescence than those from matched tissues. (B) The proportion of
SP-D binding cells in cell populations of individual H. pylori isolates
from mucus was significantly higher than those from tissue. P  0.02
(Student t test). Horizontal lines represent mean values.
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H. pylori strains (26695 and J99) (2, 49) permitted the deter-
mination of genes involved in LPS biosynthesis and thus facil-
itated the exploration of the possible genetic mechanisms un-
derlying the observed SP-D escape mechanism. At least 27
genes likely to be involved in LPS biosynthesis have been
identified in H. pylori (33). These genes are scattered through-
out the genome and not clustered at one locus. Based on the
specific changes seen in the LPS structure between J178 and
J178V, we selected genes involved in the O chain and the core
oligosaccharide region for sequence analysis. The rfaF gene
encodes an ADP-heptose-LPS heptosyltransferase II involved
in the synthesis of the heptose region of the inner core oligo-
saccharide. The fucT1 (also referred to as futA) gene encodes
an -1,3-fucosyltransferase enzyme involved in Lex and Ley
biosynthesis (2, 33, 49). This enzyme is responsible for cata-
lyzing the transfer of L-fucose from donor GDP-
-L-fucose to
the N-acetylglucosamine residues in the O chain of H. pylori
LPS at an -1, 3-glycosidic linkage (33). Recent reports indi-
cate that this FucT enzyme acts as an 3- and 4-fucosyltrans-
ferase, capable of transferring fucose to C-3 and C-4 positions
of the O-chain backbone, respectively (4, 43).
Comparison of the sequenced candidate genes of the two
strains, J178 and J178V, revealed a nonsynonymous missense
mutation in the rfaF gene sequence of J178V. The more im-
portant genetic change was found in the fucT1 gene, where the
tetranucleotide C tract in J178 lost a C base through phase
variation, probably due to a slipped-strand mispairing during
DNA replication (3). This deletion results in the formation of
an early stop codon at position 6, leading to a nonfunctional
gene product. Glucose and galactose that are found in the O
chain of J178 are more avidly bound by SP-D than fucose (42).
Hence, the structural and the genetic studies correlate with
each other and with the changes in SP-D binding affinity. The
changes in the fucT1 and rfaF genes identified in this study are
likely to explain the observed escape variation. Nevertheless,
our sequencing analyses do not rule out the presence of vari-
ations in other genes or in regulation at the posttranscriptional
level. Furthermore, alternative mechanisms of avoiding SP-D
binding may exist in other strains.
Phenotypical variation in the surface epitopes expressed by
bacteria has been well documented in Haemophilus influenzae
(45) and Neisseria spp. (52) as an adaptive strategy for micro-
bial evasion of the host immune response. The variation is
characterized by the reversible switch between “on” and “off”
statuses of a particular epitope, as well as different levels of its
expression, resulting in potential flexibility in LPS structure.
Consistent with the results of the present study, the LPS struc-
ture of H. pylori is known to be complex and phase variable
(3–5, 36, 47).
Lack of SP-D binding in clinical isolates was found to be
much more prevalent than in laboratory-adapted strains that
have been subcultured for numerous generations in the ab-
sence of SP-D. This is consistent with the possibility of SP-D
exerting selection pressure in vivo. Furthermore, SP-D binding
cells were significantly more frequent in mucus isolates than in
isolates taken from the tissue portion of samples. It appears
likely that SP-D facilitates clearance of H. pylori by trapping
the organism in the mucus layer, where it can be physically
eliminated. On the other hand, nonbinding H. pylori cells
would have a selective advantage for colonizing tissue.
Although SP-D binding can cause bacterial agglutination
and inhibition of motility (37), SP-D has been reported to be
capable of inhibiting the growth of gram-negative bacteria by
increasing membrane permeability (55). Also, SP-D aggrega-
tion of microorganisms can enhance phagocytosis by neutro-
phils and macrophages (10, 22, 39). Therefore, evasion of SP-D
binding by H. pylori may contribute to the persistence of the
infection, and thus, SP-D nonbinding variants would appear to
have an advantage over binding variants. However, SP-D bind-
ing cells were seen to persist in vivo, suggesting that there must
be a counterbalancing advantage. We found that J178 had
a growth rate advantage over J178V (maximal growth rate,
8.58  104 versus 7.6  104 CFU/hour). Thus, although J178V
rapidly switches to the J178 phenotype in the absence of SP-D
selection pressure and therefore loses the ability to evade SP-D
binding, the bacterium can gain a greater growth rate. The
reason for the differential growth rate remains unclear.
H. pylori is not the only bacterium to have developed a
strategy for avoiding SP-D-mediated elimination. A recent
study by Mariencheck and colleagues showed that Pseudo-
monas aeruginosa-produced elastase is capable of degrading
SP-D, as well as SP-A, thereby allowing the organism to evade
the SP-D-mediated immune response (26). Moreover, gram-
positive bacteria, such as Streptococcus pneumoniae, fail to
bind SP-D after serotype switching (17). Cryptococcus neofor-
mans evades SP-D through the secreted capsular component
glucuronoxylomannan (51), and encapsulation of Klebsiella
pneumoniae also facilitates SP-D evasion (46). Hence, it could
be deduced that development of strategies by pathogens to
escape SP-D binding reflects the important role of SP-D in the
innate immune response.
The prevalence of H. pylori infection in the human popula-
TABLE 3. Comparison of sequencing results of the lpxA, rfaF, and fucT1 genes from J178, J178V, and the J178V-reverted strain
(J178V round 4)
Gene Codonposition
Nucleotide sequence in Helicobacter strainsa
Transition and amino acid change
J178 J178V J178V revertedb
lpxA 10 ATT ATC ATT T3 C/Ile3 Ile
rfaF 120 TTC CTC TTC T3 C/Phen3 Leu
fucT 1 6 CCCTATTAG CCCCTATTA CCCTATTAG C base deletion at position 13 resulting
in a premature termination codon
a Boldface bases indicate the nucleotide change in the sequence. Underlining marks the position of the termination codon TAG in the fucT1 gene.
b The reverted J178V strain shows the same genotype as the parental strain, H. pylori J178.
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tion attests to the success of the organism in avoiding host
defenses. There is considerable redundancy in the innate im-
mune system, and thus, the ability of H. pylori to establish
persistent infection implies that the organism has strategies to
avoid many components. H. pylori is predominantly a nonin-
vasive bacterium, and although the gastritis associated with
infection is characterized by infiltration of the lamina propria
by neutrophils and macrophages, these phagocytic cells are not
seen in the gastric lumen or mucus at the site of colonization.
Residence in the mucus layer also minimizes the interaction of
H. pylori with other PAMP receptors, such as the Toll-like
receptors. Furthermore, a lower ability of LPSs of Helicobacter
spp. to interact with such receptors may also contribute to
persistence (25). In general, H. pylori LPS displays consider-
ably less immunoactivity than those of other gram-negative
bacteria, and it is therefore less likely to trigger an effective
response (41). Moreover, H. pylori has acquired a system for
evading complement-mediated lysis (44), and we have now
demonstrated H. pylori evasion of the collectin SP-D. These
insights into the mechanisms by which H. pylori circumvents
host defense could provide novel strategies for development of
future therapeutic approaches. If the organism is dependent
on phase variation in the fucosyltransferase gene for survival,
then targeting that enzyme may inhibit persistent infection.
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